CAMBRIDGE, Massachusetts and INGELHEIM, Germany, 14-4-2015 — /EuropaWire/ — Hydra Biosciences, Inc., a leader in the field of transient receptor potential (TRP)…
Over 950 patients have now been successfully enrolled in the pivotal Phase III HCVerso™1 and 2 trials The Phase III…